Pelis temperature-controlled packaging is delivering Covid-19 vaccines all over the UK, Europe and the Middle East.
Image courtesy Peli
With the pandemic recovery just underway, COVID-19 vaccines and therapies are rapidly becoming available for use and they must be safely distributed worldwide, within their required temperature range. Peli’s BioThermal division is providing temperature-controlled packaging to meet this critical moment, protecting these crucial payloads.
Peli’s innovative cold chain packaging has been trusted for nearly 20 years by pharmaceutical manufacturers to safely ship their life-saving products around the world. To meet the current challenge, they have adapted their existing products to provide deep frozen temperatures when required for the newly developed life sciences materials. Current and new offerings will ensure the cold chain is maintained throughout the vaccine or therapy’s journey, maximising efficacy and patient health.
“We know that pharmaceutical companies are in all phases of the development process for vaccines and therapeutics and working tirelessly to bring safe and effective drug products to market quickly,” said Greg Wheatley, Vice President of Worldwide New Product Development and Engineering at Peli BioThermal. “Our engineering team matched this urgency to ensure they have the correct temperature-controlled packaging to meet them where they’re at in drug development for the pandemic recovery, from discovery to distribution.”
Peli BioThermal’s deep frozen products use phase change material (PCM) and dry ice systems to provide frozen payload protection with durations from 72 hours to 144+ hours. Payload capacities range from one to 96 litres for parcel shippers and 140 to 1,686 litres for pallet shippers.
New deep-frozen solutions are ideal for short-term vaccine storage, redirect courier transport of vaccines from freezer farm hubs to immunisation locations and daily vaccine replenishment to remote and rural areas.
Peli BioThermal temperature-controlled packaging is currently being used to distribute COVID-19 vaccines and therapeutics, either directly or through global transportation providers, in Denmark, France, Italy, Germany, Spain, Sweden and the UK, as well as in Kuwait and Saudi Arabia in the Middle East, with more countries set to join the list as the pandemic recovery process rolls out.